Welcome to ACROBiosystems

0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Immune Checkpoint Proteins

Immune Checkpoint Proteins

Immune Checkpoint Proteins
INTRODUCTION

Immune checkpoint pathways involve both costimulatory and inhibitory proteins. The costimulatory receptors transduce signals to promote immunity against pathogens. The inhibitory receptors, on the other hand, negatively regulate T-cell activation to prevent excessive inflammation. In recent years, immune checkpoint proteins have attracted increasing attention due to their involvement in cancer development. Often times, tumor cells can hijack the checkpoint pathways to avoid attacks from the immune system. Therefore, many believe that disabling immune checkpoints would help re-engage the body’s immune system to fight against cancers. Intriguingly, anti-CTLA4 and anti-PD1 monoclonal antibodies have already demonstrated anti-tumor effect in patients with a variety of malignancies. Encouraged by this early success, researchers have expanded their investigations into other checkpoint proteins in order to find better ways to treat cancer.

To support these efforts, ACROBiosystems has developed an exclusive immune checkpoint protein collection. We offer Fc-tagged, His-tagged, Strep-tagged, and/or tag free versions of these proteins. In addition to human proteins, we also offer mouse, rat, rabbit, rhesus macaque, and cynomolgus proteins for your experimental animal studies. These products have demonstrated consistent and excellent performance in a variety of assays.

KEY FEATURES

High Quality Materials

The consistency in purity and bioactivity is essential for recombinant proteins. All our proteins have to go through stringent purity and bioactivity assessment in a variety of assays. Common standard include:


  • Purity greater than 90% by SDS-PAGE and SEC-HPLC

  • Bioactivity validated in functional ELISA and/or FACS

  • Endotoxin less than 1EU/µg by the LAL method


The purity of Human PD-L1 The purity of Human PD-L1

Fig. 1 The purity of Human PD-L1 (Cat. No. PD1-H5229) was >95% as determined by SEC-HPLC and >98% as determined by SDS-PAGE.

Human PD-L1 ELISA

Fig. 2 Bioactivity of PD1 (Cat. No. PD1-H5221) was measured in a functional ELISA against human PDL1 (Cat. No. PD1-H5258).

FACS Analysis of human PD-L1 binding to cell surface PD-1
Fig. 3 Flow Cytometry assay shows that recombinant  human PD-L1 (Cat. No. PD1-H52A3) can bind to 293 cell overexpressing human PD-1. The concentration of PD-L1 used is 0.1ug/ml (Routinely tested).
FACS Analysis of LAG-3 mFc binding to Daudi cell surface
Fig. 4 Flow Cytometry assay shows that recombinant human LAG3 mFc (Cat. No. LA3-H52Aa ) can bind to daudi cell surface. The concentration of LAG3 mFc used is 0.3ug/ml (Routinely tested)

Biotin-labeled & Heavy-labeled Proteins Available

Biotin labeling can make your assay development much easier. We offer a variety of ready-to-use biotinylated checkpoint proteins. These proteins are produced using our in-house developed labeling techniques, which confers high bioactivity and minimal batch-to-batch variation.

In addition, we also offer heavy-labeled immune checkpoint proteins, which can be used in quantitative mass spectrometry.


Inhibitor Screening Kit Available

We are now offering a PD1-PD-L1 inhibitor screening assay kit (Cat. No. EP-101) for rapid and high throughput screening of candidate inhibitory antibodies or small molecules of the PD1 pathway. This assay employs a simple colorimetric ELISA platform, which measures the binding between immobilized human PD-L1 and in-house developed biotinylated PD-1 protein.

Human PD-1 Biotin Protein Con.
Fig. 5 Immobilized PD-L1 at 2 μg/mL (100 μL/well) can bind biotinylated human PD-1 with a linear range of 0.038 - 0.6 μg/mL when detected by Streptavidin-HRP.
Log[anti-PD-1 Neutralizing Ab Con.]
Fig. 6 Inhibition of PD-1-PD-L1 binding by an anti-PD-1 neutralizing antibody is measured by the PD-1 [Biotinylated] : PD-L1 Inhibitor Screening ELISA Assay Pair (Cat. No. EP-101).
LATEST CITATIONS

Heterocyclic Compounds as Immunomodulators.

Anti-pd-1 Antibodies and Methods of Use Thereof

  • Authors:Yasmina Noubia Abdiche et al.

  • Journal:US 20160159905 A1 2016

  • Product:biotinylated Human PD-L1(Cat. No. PD1-H82E5), biotinylated Human PD-L2(Cat. No. PD2-H82E8

  • Application:Flow Cytometry

  • Request for Full-text

A Novel PD-L1-targeting Antagonistic DNA Aptamer with Antitumor Effects

Hydrogel Dual Delivered Celecoxib and Anti-PD-1 Synergistically Improve Antitumor Immunity

Therapeutic Monoclonal Antibodies in Human Breast Milk: A Case Study

This web search service is supported by Google Inc.

totop